© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Expert panelists follow a patient case to discuss locally advanced and metastatic urothelial carcinoma with a focus on frontline and maintenance therapy.
December 10th 2021
Reviewing a patient case of metastatic urothelial carcinoma, experts discuss the selection of frontline and maintenance therapy.
Shared insight on best practices in frontline maintenance therapy for metastatic urothelial carcinoma to improve patient outcomes.
December 21st 2021
Experts discuss frontline immunotherapy for metastatic urothelial carcinoma when chemotherapy may not be an option.
Experts highlight the benefits of frontline avelumab maintenance therapy in patients with metastatic urothelial carcinoma.
January 3rd 2022
Panelists consider whether the use of maintenance therapy is as prevalent after complete response or in patients with lesser PD-L1 expression.
Shared insight on how best to discuss maintenance therapy with patients being treated for metastatic urothelial carcinoma.
January 10th 2022
A brief review of whether FGFR status in metastatic urothelial carcinoma should impact treatment approaches.
Focused discussion on the duration of maintenance avelumab for metastatic urothelial carcinoma and considerations for switching therapy.
January 17th 2022
Expert perspectives on the selection of second-line therapy after a patient has progressed on maintenance avelumab.
Closing their discussion on metastatic urothelial carcinoma, panelists reflect on novel agents and the future treatment paradigm.